Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Institut Pasteur

www.pasteur.fr

Latest From Institut Pasteur

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.

Deals Business Strategies

Tech Transfer Roundup: Anixa Thinks Cleveland Clinic IP Offers Potential In Triple-Negative Breast Cancer

Anixa obtains cancer vaccine targeted to proteins common in breast cancer from Cleveland Clinic. Arxx licenses Cancer Research UK antibody that targets tumor microenvironment.

Deals Business Strategies

Tech Transfer Roundup: Tmunity Targets Pediatric Glioma With UCSF-Discovered TCR Therapy

Bayer will collaborate with start-up Hope Medicine to develop antibody therapies targeting the PRL receptor. WARF and Sanford Burnham Prebys partner on translational research.

Research & Development Deals

Tech Transfer Roundup: Roivant Taps Research Labs For New Gene Therapies

In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.

Business Strategies Commercial
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register